Skip to main content

Table 1 Categories of vaccines and immunotherapeutic studies in Phase 2 or Phase 3 trial

From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Immunotherapeutic and vaccine studies under investigation
Vaccine category Phase 2 Phase 2/3 Phase 3 Totala Ratio of Phase 3:Phase 2b
Peptide-based 93 1 18 112 1:19
Dendritic cell-based 74 3 11 88 1:15
Tumour cell-based 64 3 11 78 1:17
Virus-based 46 1 5 52 1:11
Protein-based 19 1 12 32 1:63
Anti-idiotypic antibody 18 1 9 28 1:50
Others 21 2 5 28 1:24
T cell-based 12   1 13 1:8
DNA-based 8   2 10 1:25
Bacterial-based 2   1 3 1:50
PBMC-based 2    2 NA
VLP-based 2    2 NA
Yeast-based 2    2 NA
RNA-based 1    1 NA
Grand Total 364 12 75 451 1:21
  1. aSorted by prevalence
  2. bratio of phase 3 trials: phase 2 trials